PSMA-PET/CT Findings in High-Risk Biochemically Recurrent Prostate Cancer
Author Information
Author(s): Holzgreve Adrien MD, Armstrong Wesley R. BS, Clark Kevyn J., Benz Matthias R. MD, Smith Clayton P. MD, Djaileb Loïc MD, Gafita Andrei MD, Thin Pan BS, Nickols Nicholas G. MD PhD, Kishan Amar U. MD, Rettig Matthew B. MD, Reiter Robert E. MD, Czernin Johannes MD, Calais Jeremie MD PhD
Primary Institution: University of California, Los Angeles
Hypothesis
What PSMA-PET/CT findings are present among patients with high-risk biochemically recurrent hormone-sensitive prostate cancer that is nonmetastatic as determined using conventional imaging?
Conclusion
PSMA-PET results were positive in 84% of patients, detected M1 disease stage in 46% of patients, and found polymetastatic disease in 24% of patients, indicating that conventional imaging understages high-risk nonmetastatic hormone-sensitive prostate cancer.
Supporting Evidence
- PSMA-PET detected M1 disease stage in 46% of patients.
- PSMA-PET found polymetastatic disease (≥5 lesions) in 24% of patients.
- Patients' cancers were understaged by conventional imaging.
Takeaway
Doctors used a special scan called PSMA-PET to check for cancer in men who were thought to be cancer-free, and they found that many actually had cancer that regular scans missed.
Methodology
This was a retrospective cross-sectional study analyzing PSMA-PET/CT findings in 182 patients from 4 prospective studies.
Potential Biases
The retrospective nature of the study may introduce selection bias.
Limitations
The study included fewer patients undergoing SRT and may underestimate the actual disease burden compared to the EMBARK trial.
Participant Demographics
Median age was 69 years, with patients having high-risk nonmetastatic hormone-sensitive prostate cancer.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website